Holen Sie sich die Stockscreener-App
1.32
1.49%
-0.02
Handel nachbörslich:
1.31
-0.01
-0.76%
Schlusskurs vom Vortag:
$1.34
Offen:
$1.33
24-Stunden-Volumen:
33,086
Relative Volume:
0.02
Marktkapitalisierung:
$5.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.78M
KGV:
-0.3694
EPS:
-3.5729
Netto-Cashflow:
$-4.67M
1W Leistung:
+1.54%
1M Leistung:
+15.79%
6M Leistung:
+1.54%
1J Leistung:
+647.45%
1-Tages-Spanne:
$1.305
$1.34
1-Wochen-Bereich:
$1.26
$1.40
52-Wochen-Spanne:
$0.10
$6.80
Clearmind Medicine Inc Stock (CMND) Company Profile
Firmenname
Clearmind Medicine Inc
Sektor
Branche
Telefon
-
Adresse
-
Clearmind Medicine Inc Aktie (CMND) Neueste Nachrichten
Clearmind Medicine patents new addiction treatment - Investing.com India
Clearmind Medicine patents new addiction treatment - Investing.com
SciSparc Unveils Breakthrough Ibogaine Therapy Patent - TipRanks
Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering - The Bakersfield Californian
SciSparc-Clearmind Medicine Collaboration Announces the - GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy - StockTitan
Contrasting Clearmind Medicine (NASDAQ:CMND) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Clearmind Medicine files patent for PTSD treatment compounds - Investing.com
Clearmind Medicine files patent for PTSD treatment compounds - Investing.com India
SciSparc shares up on patents filed for psychedelic compounds with Clearmind - MSN
SciSparc and Clearmind Innovate Mental Health Treatment - TipRanks
Clearmind Medicine files patent for novel MDMA therapy - Investing.com
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - Yahoo Finance UK
SciSparc-Clearmind Medicine Collaboration Leads to - GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent ... - The Bakersfield Californian
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - StockTitan
A History of Outperforming Analyst Forecasts and Beating the Odds: Clearmind Medicine Inc (CMND) - SETE News
Financial Metrics Check: Clearmind Medicine Inc (CMND)’s Ratios for Trailing Twelve Months - The Dwinnex
Clearmind and SciSparc file patent for ketamine-based therapy - Investing.com
SciSparc and Clearmind Innovate in Mental Health Therapy - TipRanks
Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment - Morningstar
SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination - Yahoo Finance
Could Psychedelics End Binge Drinking? A Breakthrough Patent Says Yes - Benzinga
CMND’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Clearmind receives patent for drug to treat binge behavior - Green Market Report
Clearmind Medicine Inc (CMND) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Clearmind Medicine secures new US patent for binge behavior regulator - Investing.com India
Clearmind Medicine secures new US patent for binge behavior regulator - Investing.com
Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment - Yahoo Finance
Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment - Morningstar
Clearmind Medicine Inc (CMND) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Is CMND’s price to cash per share ratio a concern for investors? - US Post News
Financial Metrics Unveiled: Clearmind Medicine Inc (CMND)’s Key Ratios in the Spotlight - The Dwinnex
Thinking about buying stock in Brainstorm Cell Therapeutics, Cle - GuruFocus.com
Clearmind, Yissum Apply for International Patent for Psychedelics - MarketWatch
Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders - StockTitan
Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders - Morningstar
Clearmind Medicine (NASDAQ:CMND) Stock Price Down 0.8% - Defense World
Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket - Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday - InvestorPlace
Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug - EIN News
SciSparc and Clearmind report progress in obesity treatment - Investing.com
Move over Ozempic, psychedelics might help people lose weight - Green Market Report
SciSparc’s Collaboration with Clearmind Medicine Continues - GlobeNewswire
SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug - StockTitan
Clearmind gains on exclusive global rights to psychedelic compounds for PTSD treatment - MSN
Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 - EIN News
Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research - Morningstar
Clearmind Medicine (NASDAQ:CMND) Stock Quotes, Forecast and News Summary - Benzinga
Clearmind partners for global roll-out of alcohol substitute By Investing.com - Investing.com South Africa
Clearmind partners for global roll-out of alcohol substitute - Investing.com India
Finanzdaten der Clearmind Medicine Inc-Aktie (CMND)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
1.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):